Guidance, NICE advice and quality standards in development | Guidance

Showing 251 to 260 of 386

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Peezy Midstream for urine collection (MT446)	Medical technologies guidance	TBC
Pegcetacoplan for amyotrophic lateral sclerosis [TSID10594]	Technology appraisal guidance	TBC
Pegcetacoplan for treating complement 3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]	Technology appraisal guidance	18 June 2026
Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer [TSID12021]	Technology appraisal guidance	TBC
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]	Technology appraisal guidance	29 October 2026
Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy [ID6473]	Technology appraisal guidance	TBC
Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]	Technology appraisal guidance	TBC
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]	Technology appraisal guidance	TBC
Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]	Technology appraisal guidance	TBC
Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]	Technology appraisal guidance	TBC